Keywords: مهار کننده تیروزین کیناز; epidermal growth factor receptor; nonsmall-cell lung cancer; radiotherapy; radiation recall pneumonitis; tyrosine kinase inhibitor
مقالات ISI مهار کننده تیروزین کیناز (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: مهار کننده تیروزین کیناز; AC; adenocarcinoma; EGFR; epidermal growth factor receptor; ERCC1; Excision repair cross-complementation group 1; LCNEC; large cell neuroendocrine carcinoma; NSCLC; non-small cell lung carcinoma; OS; overall survival; SCLC; small cell lung carcinoma; SST;
Keywords: مهار کننده تیروزین کیناز; Tyrosine Kinase Inhibitor; Chemotherapy; Formulation; Bioavailability;
Keywords: مهار کننده تیروزین کیناز; Epidermal growth factor receptor mutations; Non-small cell lung cancer; Tyrosine kinase inhibitor; Osimertinib; Rociletinib; HM61713
Keywords: مهار کننده تیروزین کیناز; Chronic myeloid leukemia; Tyrosine kinase inhibitor; Switch; Early molecular response; Deep molecular response;
Keywords: مهار کننده تیروزین کیناز; Biomarker; Renal cell carcinoma; Tyrosine kinase inhibitor; VEGF; Targeted therapy;
Keywords: مهار کننده تیروزین کیناز; Discontinuation; Kidney cancer; mTOR inhibitor; Overall survival; Progression-free survival; Tyrosine kinase inhibitor;
Keywords: مهار کننده تیروزین کیناز; Ab; antibody; ACT; adoptive cell therapy; ANG; angiopoietin; ATP; adenosine triphosphate; BMDC; bone marrow derived cell; CA4P; combretastatin A phosphate; CAF; cancer-associated fibroblast; CCL2; C-C motif ligand 2; CD; cluster differentiation antigen; C
Keywords: مهار کننده تیروزین کیناز; AE; adverse event; ALL; acute lymphoblastic leukemia; alloSCT; allogeneic hematopoietic stem cell transplant; AYA; adolescent and young adult; BFM; Berlin-Frankfurt-Münster; CAR-T; chimeric antigen receptor-modified T cell; CCyR; complete cytogenetic r
Keywords: مهار کننده تیروزین کیناز; Ang1/2; angiopoietin 1 or 2; BMPR2; Bone morphogenetic protein receptor type 2; CAV-1/2; caveolin-1/2; CHD; congenital heart disease; EC; endothelial cell; ECFC; endothelial colony forming cells; EGR-1; early growth response protein 1; EndoMT; endothelial
Keywords: مهار کننده تیروزین کیناز; CAPRI; Ca2+-promoted RAS inactivator; CRMP-2; collapsin response mediator protein-2; CSRD; cysteine/serine-rich domain; CTD; C-terminal domain; ERK; extracellular signal-regulated kinase; FTI; farnesyltransferase inhibitor; FAK1; focal adhesion kinase 1;
Keywords: مهار کننده تیروزین کیناز; BCR-ABL1; Chronic myeloid leukemia; Dose intensity; Philadelphia chromosome; Ponatinib; Tyrosine kinase inhibitor;
Keywords: مهار کننده تیروزین کیناز; AM; adrenomedullin; AMF; autocrine motility factor; AML; acute myeloid leukemia; BCL; B-cell lymphoma; BCR; breakpoint cluster region; BM; bone marrow; CCL; chemokine (CâC motif) ligand; CML; chronic myeloid leukemia; ECM; extracellular matrix; EGF; epi
Keywords: مهار کننده تیروزین کیناز; Cancer stem cell; Chemotherapy; Chemoresistance; Targeted therapy; 5-FU; 5-fluorouracil; ABCT; ATP-binding cassette transporter; ALDH; Aldehyde dehydrogenase; AML; Acute myeloid leukemia; ASC; Adult stem cell; BCRP or ABCG; Breast cancer resistance protei
Keywords: مهار کننده تیروزین کیناز; Drug-induced immune thrombocytopenia; Imatinib; Myelosuppression; Thrombocytopenia; Tyrosine kinase inhibitor
Keywords: مهار کننده تیروزین کیناز; Acute myeloid leukemia; Philadelphia chromosome; Tyrosine kinase inhibitor; Allogeneic stem cell transplantation
Keywords: مهار کننده تیروزین کیناز; Chronic myelogenous leukemia; Comorbid conditions; NCCN guidelines; Treatment choice; Tyrosine kinase inhibitor;
Keywords: مهار کننده تیروزین کیناز; Chronic myeloid leukemia; Tyrosine kinase inhibitor; Imatinib mesylate; Allogeneic stem cell transplantation;
Keywords: مهار کننده تیروزین کیناز; CR; complete response; CNR; contrast-to-noise ratio; GIST; gastrointestinal stromal tumor; PD; progressive disease; PDGFRA; platelet-derived growth factor receptor A; PET; positron-emission tomography; PFI; progression-free interval; PR; partial response;
Keywords: مهار کننده تیروزین کیناز; Hepatocellular carcinoma; Sarcopenia; Sorafenib; Tyrosine kinase inhibitor; Visceral fat area;
Keywords: مهار کننده تیروزین کیناز; mCRPC; Pain control; Patient-reported outcomes; Phase 2 trial; Quality of life; Tyrosine kinase inhibitor
Keywords: مهار کننده تیروزین کیناز; Drug metabolization; Tyrosine kinase inhibitor; Orbital ion trap; Fragmentation; Exact mass
Keywords: مهار کننده تیروزین کیناز; adherence; chronic myeloid leukemia; duration; switching; tyrosine kinase inhibitor;
Keywords: مهار کننده تیروزین کیناز; Tyrosine kinase inhibitors; Drug transporter; Drug interaction; Therapeutic drug monitoring; Skin disorders; ADR; Adverse drug reaction; AUC; Area under the curve; BBB; Blood-brain barrier; BCRP/ABCG2; Breast cancer resistance protein; CNS; Central nerv
Keywords: مهار کننده تیروزین کیناز; Epidermal growth factor receptor; Optimal treatment regimen; Tyrosine kinase inhibitor;
Keywords: مهار کننده تیروزین کیناز; Renal cell carcinoma; Tyrosine kinase inhibitor; Sequence of systemic therapies; Combination of systemic therapies
Keywords: مهار کننده تیروزین کیناز; Hematopoietic stem cell transplantation; KIT; Mast cells; Myeloproliferative neoplasm; Tyrosine kinase inhibitor
Keywords: مهار کننده تیروزین کیناز; Allogeneic hematopoietic stem cell transplantation; Chronic myelogenous leukemia; Philadelphia chromosome; Tyrosine kinase inhibitor;
Keywords: مهار کننده تیروزین کیناز; Tyrosine kinase inhibitor; NSCLC; Cranial radiotherapy; Neurotoxicity; EGFR; ALK
Keywords: مهار کننده تیروزین کیناز; Chronic myeloid leukemia; Tyrosine kinase inhibitor; Hematopoietic stem cell transplant; BCR-ABL1;
Keywords: مهار کننده تیروزین کیناز; Glioblastoma; Treatment; Review; Pharmacology; Targeted therapy; Stem cell; AKT; protein kinase B; BBB; blood-brain barrier; BCNU; carmustin; CCNU; lomustin; c-MET; hepatocyte growth factor receptor; EGF(R); epidermal growth factor (receptor); EGFRvIII; e
Keywords: مهار کننده تیروزین کیناز; 2DG; 2-deoxy-glucose; 6-AN; aminocicotinamide; ABC; ATP-binding cassette transporter; CSCs; cancer stem cells; DCA; dichloroacetate; G6PD; glucose-6-phosphate dehydrogenase; GLUT; glucose transporter; HIF; hypoxia-inducible factors; HK2; hexokinase 2; Kra
Keywords: مهار کننده تیروزین کیناز; Chronic myelogenous leukemia; Tyrosine kinase inhibitor; Resistance; BM microenvironment;
Keywords: مهار کننده تیروزین کیناز; 2 DE; 2-dimensional electrophoresis; ABPP; activity-based protein profiling; BFGF; basic fibroblast growth factor; CML; chronic myeloid leukemia; CRC; colorectal cancer; DIGE; differential in gel electrophoresis; EGF(R); epidermal growth factor (receptor)
Keywords: مهار کننده تیروزین کیناز; ALK; anaplastic lymphoma kinase; EGFR; epidermal growth factor receptor; FGFR; fibroblast growth factor receptor; FISH; fluorescence in situ hybridization; MET; mesenchymal epithelial transition; NGS; next-generation sequencing; SQCC; squamous cell carcin
Keywords: مهار کننده تیروزین کیناز; JCOG; Japan Clinical Oncology Group; SCLC; small cell lung cancer; ED; extensive disease; OS; overall survival; WJOG; West Japan Oncology Group; NSCLC; non-small-cell lung cancer; EGFR; epidermal growth factor receptor; PFS; progression-free survival; TKI
Keywords: مهار کننده تیروزین کیناز; EGFR; epidermal growth factor receptor; NSCLC; non-small cell lung cancer; TKI; tyrosine kinase inhibitor; WT; wild type; KRAS; Kirsten RNA associated rat sarcoma 2 virus gene; PTEN; phosphatase and tensin homolog; HGF; hepatocyte growth factor; IGF1R; in
Keywords: مهار کننده تیروزین کیناز; ADAM; (a disintegrin and metalloprotease) metallopeptidase; ALPs; alkyl-lysophospholipids; CD24; signal transducer CD24 (glycosylphosphatidylinositol-anchored receptor); CD44; CD44 antigen (receptor for hyaluronic acid); CXCR4; chemokine receptor type 4;
Keywords: مهار کننده تیروزین کیناز; Acquired resistance; BCR-ABL1; Kinase domain mutation; Tyrosine kinase inhibitor; T315I
Keywords: مهار کننده تیروزین کیناز; 5FU; 5-fluorouracile; ABC; ATP-binding cassette; AUC; area under the curve; BCRP; breast cancer resistance protein; Cmax; maximum (peak) plasma concentration; CYP; cytochrome p450 enzymes; DDI; drug-drug interactions; EIAEDS; enzyme-inducing antiepilept
Keywords: مهار کننده تیروزین کیناز; BCR-ABL1; Clonogenic assay; Colony; Minimal residual disease; Tyrosine kinase inhibitor;
Keywords: مهار کننده تیروزین کیناز; Renal cell carcinoma; Tyrosine kinase inhibitor; Axitinib; Tivozanib; Dovitinib; Cabozantinib;
Keywords: مهار کننده تیروزین کیناز; EGFR; GM-CSF; IL-8; Head and neck squamous cell carcinoma; Survival; Acquired resistance; Serum protein signature; TIMP-1; Tyrosine kinase inhibitor; VEGF;
Keywords: مهار کننده تیروزین کیناز; Anti-angiogenesis; Resistance; Targeted therapies; Predictive markers; Autophagy; AKT/PKB; protein kinaseB; BMDCs; bone marrow-derived cells; BVZ; bevacizumab/Avastin; CSC; cancer stem-like cells; EGF; epidermal growth factor; EPC; endothelial progenitor
Keywords: مهار کننده تیروزین کیناز; APD90; action potential duration at 90% repolarization; BDM; 2,3-butanedione monoxime; BTS; N-benzyl-p-toluene sulphonamide; Cav1.2; calcium channel produced from the CACNA1C gene; cTnI; cardiac troponin I; C-E curve; concentration-effect curve; Cx43; con
Keywords: مهار کننده تیروزین کیناز; Evaluation of lung cancer treatment; Personalized medicine; Tyrosine kinase inhibitor; Antiangiogenic; Immunotherapy
Ascending Single-Dose Study of the Safety Profile, Tolerability, and Pharmacokinetics of Bosutinib Coadministered With Ketoconazole to Healthy Adult Subjects
Keywords: مهار کننده تیروزین کیناز; bosutinib; ketoconazole; pharmacokinetics; tyrosine kinase inhibitor;
Accuracy of the cobas EGFR Mutation Assay in Non-small-cell Lung Cancer Compared With Three Laboratory-developed Tests
Keywords: مهار کننده تیروزین کیناز; Genetic mutation; In vitro diagnostics; Laboratory test; Tissue section; Tyrosine kinase inhibitor;
Predictors of Long-Term Response With Pazopanib in Patients With Advanced Renal-Cell Carcinoma
Keywords: مهار کننده تیروزین کیناز; Angiogenesis inhibitors; Kidney cancer; RCC; Tyrosine kinase inhibitor; Vascular endothelial growth factor;
Identification of chronic myeloid leukemia patients treated with imatinib who are potentially eligible for treatment discontinuation by assessing real-life molecular responses on the international scale in a EUTOS-certified lab
Keywords: مهار کننده تیروزین کیناز; CML; chronic myeloid leukemia; CML-CP; chronic myeloid leukemia in chronic phase; DMR; deep molecular response; ELN; European LeukemiaNet; ENESTFreedom; Evaluating Nilotinib Efficacy and Safety in Clinical Trials - Following REsponsE in De nOvo CML-CP P